Norstat agrees deal for Swiss research services firm

The deal will add to Norstat’s Swiss operations, following the acquisition of Zurich-based TestingTime in 2021 and the recent appointment of Raúl Fuertes as business development director for the region.
DemoSCOPE was founded in 1961 and operates from offices in Lucerne and Fribourg, focused on data collection and research services across quantitative and qualitative research, as well as running a panel of more than 60,000 respondents in Switzerland.
Dr Michael Buess (pictured right) will continue as managing director at DemoSCOPE, working with the Norstat team.
Erling Eriksen (pictured left), chief executive at Norstat, said: “As a trusted and well-established data collection provider in Switzerland, DemoSCOPE is a strong strategic fit for us.
“Switzerland is an important market, and with its experienced team, deep expertise in both social and consumer research, high-quality panel and long-standing client relationships, DemoSCOPE further strengthens our position.”
Buess added: “We are incredibly proud of what DemoSCOPE has achieved over many decades in the Swiss market through high-quality work and trusted client relationships.
“Becoming part of Norstat marks an exciting new chapter for us and is a natural fit with the values that define DemoSCOPE. It allows us to combine our deep local expertise with Norstat’s global operational excellence, creating a more comprehensive offering for our existing clients while also enabling us to expand into new client segments.”
We hope you enjoyed this article.
Research Live is published by MRS.
The Market Research Society (MRS) exists to promote and protect the research sector, showcasing how research delivers impact for businesses and government.
Members of MRS enjoy many benefits including tailoured policy guidance, discounts on training and conferences, and access to member-only content.
For example, there's an archive of winning case studies from over a decade of MRS Awards.
Find out more about the benefits of joining MRS here.








0 Comments